Luke Halpern is an assistant editor with Pharmacy Times. Luke wrote for Pharmacy Times in the summer of 2023, and assumed a full-time role in June 2024. His work has been featured in Pharmacy Times and the American Journal of Managed Care. He graduated from the University of Massachusetts, Amherst in May 2024.
As Chemotherapy Drug Shortage Continues, Unimaginable Decisions and Lacking Accountability Reign
July 24th 2023Treatment providers have been forced to adapt and make potentially life-altering decisions for patients due to persistent chemotherapy drug shortages, all while solutions from the FDA and drug manufacturers remain scant.
Read More
Mode of Cell Cycle Dysregulation in Cancer Formation Affects Disease Characteristics
July 21st 2023Previous research has determined the role of dysregulation in the evolution of cancers but lacked investigation of the ability of these mutations to predict different forms and aggressiveness of cancer.
Read More
American Diabetes Association Highlights New Developments in Diabetes Technology
June 26th 2023The American Diabetes Association showcased advancements in diabetes technology revolving around improving glucose control devices and treating diabetic retinopathy at the 83rd Scientific Sessions.
Read More
Patients with ST-segment elevation myocardial infarction who are uninsured were not found to be transferred between facilities at a higher rate than insured patients, and the amount of transfers were instead based more on the capability of a facility to provide percutaneous coronary intervention in a timely fashion.
Read More
New Model Risk Factors for HIV in Women Include Pregnancy, Hepatitis C, and Substance Use
June 23rd 2023Model produces information that can lead to individual providers identifying women who may need more targeted and more frequent HIV testing or be good candidates for preexposure prophylaxis.
Read More
Liso-Cel Produces Deep, Durable Responses in Patients with Hard-to-Treat Lymphomas
June 22nd 2023Treatment with lisocabtagene maraleucel led to strong and durable response rates with little serious adverse effects in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma.
Read More
Common Antibiotics Associated with C. difficile Infection Include Piperacillin, Meropenem
June 21st 2023Antibiotics that were found to be most commonly associated with clostridium difficile infection are piperacillin/tazobactam, meropenem, vancomycin, ciprofloxacin, ceftriaxone, and levofloxacin, according to a recent study.
Read More